{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T02:44:17Z","timestamp":1787453057469,"version":"build-2736575974"},"reference-count":59,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2015,10,20]]},"published-print":{"date-parts":[[2016,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      To assess the risk of solid organ transplant (SOT) rejection after vaccination with the adjuvanted (AS03) A\/H1N1 2009 pandemic influenza vaccine\n                      <jats:italic>Pandemrix<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Self-controlled case series (SCCS) in the UK Clinical Practice Research Datalink (CPRD) and its linked component of the Hospital Episodes Statistics (HES) inpatient database. Analyses were conducted using the SCCS method for censored, perturbed or curtailed post-event exposure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>\n                      Of the 184 transplant recipients having experienced at least one SOT rejection (liver, kidney, lung, heart or pancreas) during the study period from 1 October 2009 to 31 October 2010, 91 participants were included in the main analysis, of which 71 had been exposed to\n                      <jats:italic>Pandemrix<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome measures<\/jats:title>\n                    <jats:p>\n                      Occurrence of SOT rejection during risk (30 and 60\u2005days after any\n                      <jats:italic>Pandemrix<\/jats:italic>\n                      dose) and control periods. Covariates in the CPRD included time since transplantation, seasonal influenza vaccination, bacterial and viral infections, previous SOT rejections and malignancies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The relative incidence (RI) of rejection of any one of the five transplanted organs, adjusted for time since transplantation, was 1.05 (95% CI 0.52 to 2.14) and 0.80 (95% CI 0.42 to 1.50) within 30 and 60\u2005days after vaccination, respectively. Similar estimates were observed for rejection of a kidney only, the most commonly transplanted organ (RI within 30\u2005days after vaccination: 0.85 (95% CI 0.38 to 1.90)). Across various models and sensitivity analyses, RI estimates remained stable and within a consistent range around 1.0.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      These results suggest a reassuring safety profile for\n                      <jats:italic>Pandemrix<\/jats:italic>\n                      with regard to the risk of rejection in SOT recipients in England and contribute to inform the benefit\u2013risk of AS03-adjuvanted pandemic influenza vaccines in transplanted patients in the event of future pandemics.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>NCT01715792.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2015-009264","type":"journal-article","created":{"date-parts":[[2016,1,28]],"date-time":"2016-01-28T22:53:56Z","timestamp":1454021636000},"page":"e009264","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":25,"title":["Effect of the adjuvanted (AS03) A\/H1N1 2009 pandemic influenza vaccine on the risk of rejection in solid organ transplant recipients in England: a self-controlled case series"],"prefix":"10.1136","volume":"6","clinical-trial-number":[{"clinical-trial-number":"nct01715792","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Catherine","family":"Cohet","sequence":"first","affiliation":[{"name":"Global Epidemiology, GSK Vaccines, Wavre, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Haguinet","sequence":"additional","affiliation":[{"name":"Global Epidemiology, GSK Vaccines, Wavre, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00ebl","family":"Dos Santos","sequence":"additional","affiliation":[{"name":"Business & Decision Life Sciences, Brussels, Belgium (on behalf of GSK Vaccines)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave","family":"Webb","sequence":"additional","affiliation":[{"name":"Department of R&D, GSK, Uxbridge, Middlesex, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Logie","sequence":"additional","affiliation":[{"name":"Department of R&D, GSK, Uxbridge, Middlesex, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Germano","family":"LC Ferreira","sequence":"additional","affiliation":[{"name":"Global Epidemiology, GSK Vaccines, Wavre, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Rosillon","sequence":"additional","affiliation":[{"name":"Global Epidemiology, GSK Vaccines, Wavre, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Shinde","sequence":"additional","affiliation":[{"name":"Global Epidemiology, GSK Vaccines, Wavre, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2016,1,28]]},"reference":[{"key":"2025121411093754000_6.1.e009264.1","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/QCO.0b013e328355a79b","article-title":"Influenza vaccines in the setting of solid-organ transplantation: are they safe?","volume":"25","author":"Avery","year":"2012","journal-title":"Curr Opin Infect Dis"},{"key":"2025121411093754000_6.1.e009264.2","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/MOT.0b013e3283592622","article-title":"Influenza vaccination in solid-organ transplant recipients","volume":"17","author":"Cordero","year":"2012","journal-title":"Curr Opin Organ Transplant"},{"key":"2025121411093754000_6.1.e009264.3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2011.03753.x"},{"key":"2025121411093754000_6.1.e009264.4","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2217\/imt.13.171","article-title":"Influenza vaccination in immunocompromised patients: efficacy and safety","volume":"6","author":"Zbinden","year":"2014","journal-title":"Immunotherapy"},{"key":"2025121411093754000_6.1.e009264.5","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr278"},{"key":"2025121411093754000_6.1.e009264.6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2011.03604.x"},{"key":"2025121411093754000_6.1.e009264.7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2011.03743.x"},{"key":"2025121411093754000_6.1.e009264.8","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181ca56f8"},{"key":"2025121411093754000_6.1.e009264.9","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199903150-00019"},{"key":"2025121411093754000_6.1.e009264.10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02787.x"},{"key":"2025121411093754000_6.1.e009264.11","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05430610"},{"key":"2025121411093754000_6.1.e009264.12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2004.00564.x"},{"key":"2025121411093754000_6.1.e009264.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2004.03.004"},{"key":"2025121411093754000_6.1.e009264.14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2007.02066.x"},{"key":"2025121411093754000_6.1.e009264.15","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1399-3046.2010.01433.x","article-title":"Early post-transplant vaccination with pandemic influenza A\/H1N1 vaccine in pediatric heart transplant recipients","volume":"15","author":"Altamirano-Diaz","year":"2011","journal-title":"Pediatr Transplant"},{"key":"2025121411093754000_6.1.e009264.16","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04670511"},{"key":"2025121411093754000_6.1.e009264.17","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02160311"},{"key":"2025121411093754000_6.1.e009264.18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2011.01391.x"},{"key":"2025121411093754000_6.1.e009264.19","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jpeds.2010.10.034","article-title":"Acceptance and adverse events of the 2009 H1N1 vaccination in immunosuppressed pediatric liver transplant recipients","volume":"158","author":"Goldschmidt","year":"2011","journal-title":"J Pediatr"},{"key":"2025121411093754000_6.1.e009264.20","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1097\/TP.0b013e3182115be0","article-title":"Antibody response after a single dose of an AS03-adjuvanted split-virion influenza A (H1N1) vaccine in heart transplant recipients","volume":"91","author":"Meyer","year":"2011","journal-title":"Transplantation"},{"key":"2025121411093754000_6.1.e009264.21","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/j.1399-3062.2012.00769.x","article-title":"Antibody response to the non-adjuvanted and adjuvanted influenza A H1N1\/09 monovalent vaccines in renal transplant recipients","volume":"14","author":"Salles","year":"2012","journal-title":"Transpl Infect Dis"},{"key":"2025121411093754000_6.1.e009264.22","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.healun.2011.01.707","article-title":"Pandemic 2009 H1N1 influenza virus vaccination in lung transplant recipients: coverage, safety and clinical effectiveness in the Zurich cohort","volume":"30","author":"Schuurmans","year":"2011","journal-title":"J Heart Lung Transplant"},{"key":"2025121411093754000_6.1.e009264.23","doi-asserted-by":"crossref","first-page":"893","DOI":"10.3851\/IMP2103","article-title":"Responses of solid organ transplant recipients to the AS03-adjuvanted pandemic influenza vaccine","volume":"17","author":"Siegrist","year":"2012","journal-title":"Antivir Ther (Lond)"},{"key":"2025121411093754000_6.1.e009264.24","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.1016\/j.vaccine.2011.04.012","article-title":"Immunogenicity of inactivated 2009 H1N1 influenza vaccine in pediatric liver transplant recipients","volume":"29","author":"Torii","year":"2011","journal-title":"Vaccine"},{"key":"2025121411093754000_6.1.e009264.25","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.healun.2010.07.011","article-title":"H1N1 influenza vaccination and infection in pediatric heart transplants","volume":"29","author":"Vazquez-Alvarez Mdel","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"2025121411093754000_6.1.e009264.26","doi-asserted-by":"crossref","first-page":"pii: 19763","DOI":"10.2807\/ese.16.02.19763-en","article-title":"Effectiveness of pandemic and seasonal influenza vaccine in preventing pandemic influenza A(H1N1)2009 infection in England and Scotland 2009\u20132010","volume":"16","author":"Hardelid","year":"2011","journal-title":"Euro Surveill"},{"key":"2025121411093754000_6.1.e009264.27","unstructured":"Sethi M , Pebody R . Pandemic H1N1 (swine) influenza vaccine uptake amongst patient groups in primary care in England 2009\/10. Departement of Health\u2014Health Protection Agency, 2010. https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/215977\/dh_121014.pdf (accessed 27 Feb 2015)."},{"key":"2025121411093754000_6.1.e009264.28","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyv098"},{"key":"2025121411093754000_6.1.e009264.29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2009.03537.x"},{"key":"2025121411093754000_6.1.e009264.30","doi-asserted-by":"publisher","DOI":"10.1177\/2042098611435911"},{"key":"2025121411093754000_6.1.e009264.31","unstructured":"Health and Social Care Information Centre. Hospital Episode Statistics. http:\/\/www.hscic.gov.uk\/hes (accessed 27 Feb 2015)."},{"key":"2025121411093754000_6.1.e009264.32","doi-asserted-by":"publisher","DOI":"10.1093\/eurpub\/cks046"},{"key":"2025121411093754000_6.1.e009264.33","unstructured":"Department of Health\/Health Protection Agency. Pandemic H1N1 (swine) influenza vaccine uptake amongst patient groups in primary care in England 2009\/10. http:\/\/www.dh.gov.uk\/prod_consum_dh\/groups\/dh_digitalassets\/@dh\/@en\/@ps\/documents\/digitalasset\/dh_121014.pdf (accessed 27 Jan 2014)."},{"key":"2025121411093754000_6.1.e009264.34","unstructured":"Department of Health, United Kingdom. Pandemic H1N1 Vaccine Uptake Figures for England by SHA and PCT. http:\/\/webarchive.nationalarchives.gov.uk\/20130107105354\/http:\/www.dh.gov.uk\/en\/Publicationsandstatistics\/Publications\/PublicationsPolicyAndGuidance\/DH_114203 (accessed 25 Mar 2015)."},{"key":"2025121411093754000_6.1.e009264.35","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268811001531"},{"key":"2025121411093754000_6.1.e009264.36","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2302"},{"key":"2025121411093754000_6.1.e009264.37","doi-asserted-by":"publisher","DOI":"10.1093\/biostatistics\/kxn013"},{"key":"2025121411093754000_6.1.e009264.38","doi-asserted-by":"publisher","DOI":"10.2307\/2533328"},{"key":"2025121411093754000_6.1.e009264.39","unstructured":"SAS Institute. Editorial Guidelines. http:\/\/www.sas.com\/en_us\/legal\/editorial-guidelines.html (accessed 25 Mar 2015)."},{"key":"2025121411093754000_6.1.e009264.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.08.069"},{"key":"2025121411093754000_6.1.e009264.41","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e7594"},{"key":"2025121411093754000_6.1.e009264.42","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1016\/j.vaccine.2013.08.024","article-title":"Bivalent human papillomavirus vaccine and the risk of fatigue syndromes in girls in the UK","volume":"31","author":"Donegan","year":"2013","journal-title":"Vaccine"},{"key":"2025121411093754000_6.1.e009264.43","unstructured":"Musonda P . The self-controlled case series method: performance and design in studies of vaccine safety [PhD thesis]. The Open University, 2006."},{"key":"2025121411093754000_6.1.e009264.44","doi-asserted-by":"crossref","first-page":"e82222","DOI":"10.1371\/journal.pone.0082222","article-title":"Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccines: a multinational self-controlled case series in Europe","volume":"9","author":"Romio","year":"2014","journal-title":"PLoS ONE"},{"key":"2025121411093754000_6.1.e009264.45","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis597"},{"key":"2025121411093754000_6.1.e009264.46","doi-asserted-by":"crossref","first-page":"574","DOI":"10.5694\/mja12.10534","article-title":"Guillain-Barre syndrome following pandemic (H1N1) 2009 influenza A immunisation in Victoria: a self-controlled case series","volume":"197","author":"Crawford","year":"2012","journal-title":"Med J Aust"},{"key":"2025121411093754000_6.1.e009264.47","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jpeds.2015.03.038","article-title":"Intussusception and monovalent rotavirus vaccination in Singapore: self-controlled case series and risk-benefit study","volume":"167","author":"Yung","year":"2015","journal-title":"J Pediatr"},{"key":"2025121411093754000_6.1.e009264.48","unstructured":"Klein A , Lewis C , Madsen J . Organ Transplant. A Clinical Guide, 2011, Cambridge University Press, Section 2 (p63\u201369), Section 3 (p122\u2013127), Section 4 (p173\u2013181), Section 5 (p231\u2014237) and Section 6 (p286\u2014294)."},{"key":"2025121411093754000_6.1.e009264.49","unstructured":"European Society for Organ Transplantation. http:\/\/www.esot.org\/ESOT\/home (accessed 25 Mar 2015)."},{"key":"2025121411093754000_6.1.e009264.50","unstructured":"L\u00e4kemedelsverket Medical Products Agency. Final summary of adverse drug reaction reports in Sweden with Pandemrix through October 2009 \u2013mid April 2010. 2010. http:\/\/www.lakemedelsverket.se\/upload\/eng-mpa-se\/Pandemrix%20ADRs%20in%20Sweden%2015%20april%202010.pdf (accessed 27 Feb 2015)."},{"key":"2025121411093754000_6.1.e009264.51","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.pneumo.2011.06.004","article-title":"H1N1 (2009) influenza A infection in transplant recipient patients: a comparative study versus non-transplanted patients","volume":"67","author":"Crockett","year":"2011","journal-title":"Rev Pneumol Clin"},{"key":"2025121411093754000_6.1.e009264.52","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2010.05.007"},{"key":"2025121411093754000_6.1.e009264.53","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1590\/S0101-28002011000200004","article-title":"Clinical manifestations and evolution of infection by influenza A (H1N1) in kidney transplant recipients","volume":"33","author":"Freitas","year":"2011","journal-title":"J Bras Nefrol"},{"key":"2025121411093754000_6.1.e009264.54","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(10)70133-X"},{"key":"2025121411093754000_6.1.e009264.55","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1097\/TP.0b013e3181f546cf","article-title":"Pandemic (H1N1) 2009 infection in adult solid organ transplant recipients in Singapore","volume":"90","author":"Low","year":"2010","journal-title":"Transplantation"},{"key":"2025121411093754000_6.1.e009264.56","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1111\/j.1432-2277.2010.01193.x","article-title":"Pancreas rejection after pandemic influenza virus A(H1N1) vaccination or infection: a report of two cases","volume":"24","author":"Vistoli","year":"2011","journal-title":"Transpl Int"},{"key":"2025121411093754000_6.1.e009264.57","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2010.09.144"},{"key":"2025121411093754000_6.1.e009264.58","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis487"},{"key":"2025121411093754000_6.1.e009264.59","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/MOT.0b013e3283636c88","article-title":"Immunization in transplantation: review of the recent literature","volume":"18","author":"Pittet","year":"2013","journal-title":"Curr Opin Organ Transplant"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2015-009264","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T19:09:46Z","timestamp":1765739386000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2015-009264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,1,28]]},"published-print":{"date-parts":[[2016,1]]}},"alternative-id":["10.1136\/bmjopen-2015-009264"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2015-009264","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1]]}}}